Physician Views Poll: Gauging US prescriber reaction to Teva's AirDuo pricing strategy

Teva's newly launched AirDuo RespiClick asthma treatment may not represent true generic competition to GlaxoSmithKline's multi-billion dollar Advair franchise, but by launching its branded version and an authorised generic simultaneously, the Israeli drugmaker will compete aggressively on price (ViewPoints: A generic by any other name – will stakeholders buy in on Teva's kinda sorta generic equivalent to Advair?).

AirDuo is not substitutable for Advair and uses Teva's own RespiClick inhaler, but clinical data have demonstrated similar efficacy at lower doses of medication. With the in-house authorised generic costing approximately a third of Advair and AirDuo, will prescribers be swayed by Teva's pricing gamble? We are snap polling US pulmonologists and primary care physicians to find out…

Teva has recently launched AirDuo (fluticasone/salmeterol) – a non-substitutable (AB-rated) equivalent to GlaxoSmithKline's Advair, which is administered using Teva's RespiClick inhaler, for the treatment of asthma (not COPD). The product will be priced similarly to Advair.

Are you aware of this product/anticipating early utilisation? (i.e. over next 12 months)


Yes – marginal early use

Yes – moderate early use

Yes – significant early use

Yes – very significant early use

Teva has also launched an 'authorised generic' version of its own product (AirDuo), which has a list price approximately a third of branded AirDuo and Advair ($90 a month). Do you think this lower price will encourage use of the authorised generic among patients and prescribers?


Yes – marginally

Yes – moderately

Yes – significantly

Yes – very significantly

Teva's label states that "fluticasone propionate/salmeterol xinafoate MDPI 118/13.2 mcg (AirDuo) had similar clinical efficacy with lower systemic exposure when compared to the 50 mcg of salmeterol in fluticasone propionate/salmeterol 100/50 mcg dry powder inhaler (Advair)." Is this opportunity to prescribe a lower but equally effective dose to asthma patients clinically compelling?


Yes – marginally so

Yes – moderately so

Yes – significantly so

Yes – very significantly so

If the lower price of authorised generic AirDuo meant this product was given preferred status on insurance plans (and branded ICS/LABA combinations excluded) how would you react?

Support it – generics have been approved by FDA and makes sense for the system

Accept it – an inconvenience but this is an FDA-approved product and makes sense for the system

Quite unhappy – worried about material differences between products and/or difference in inhaler; will be situations where I insist on using branded version

Reject it – I would actively seek to reject in most cases

Other (please state)

How comfortable would you be switching a stable asthma patient from branded Advair to AirDuo?

Very uncomfortable

Moderately uncomfortable

Slightly uncomfortable

Neither comfortable or uncomfortable

Slightly comfortable

Moderately comfortable

Very comfortable

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions. Note: FirstWord Polls are powered by MedePolls, a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties and over 100 markets. To conduct this poll with a different audience, or an entirely different poll, contact us at

To read more Physician Views articles, click here.